FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.

Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...

Methotrexate (MTX) is a drug that has been used to treat psoriatic arthritis (PsA) for more than 40 years. Alone or in combination with other therapies, MTX is considered a first-line treatment ...

Rebecca Haberman, MD, of NYU Langone Health, highlights precision medicine and potential prevention strategies, two areas of promising psoriatic arthritis research.

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbus ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

SUGAR LAND, Texas--(BUSINESS WIRE)--FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric clinical trial, to evaluate if ...

FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric ... arthritis, chronic musculoskeletal pain, severe osteoarthritis ...